2020年度肺癌放射治疗领域研究进展

摘要/Abstract

摘要：放疗作为肺癌主要的治疗方式之一,在肺癌全程管理中均发挥重要作用。2020年肺癌放疗领域成绩瞩目,放疗免疫联合治疗依然是热点,靶向联合放疗策略及放疗剂量和技术选择备受瞩目。本文对2020年度肺癌放疗领域的重要研究进行归纳总结。

中图分类号:

R734.2

刘洁, 李炫宗, 于金明. 2020年度肺癌放射治疗领域研究进展[J]. betway必威登陆网址（betway.com ）学报, 2021, 42(5): 321-326.

Liu Jie, Li Xuanzong, Yu Jinming. Research on the progress in radiotherapy of lung cancer in 2020[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2021, 42(5): 321-326.

参考文献

[1] Gao S, Li N, Wang S, et al. Lung cancer in people's republic of China[J]. J Thorac Oncol, 2020, 15(10):1567.
[2] Kelly K, Daly ME, Mirhadi A, et al. Atezolizumab plus stereotactic ablative therapy for medically inoperable patients with early-stage non-small cell lung cancer[J]. Journal of Clinical Oncology, 2020, 38(15_suppl):9011.
[3] Chang JY, Lin SH, Yao L, et al. I-SABR phase II randomized study of nivolumab immunotherapy and stereotactic ablative radiotherapy in early stage NSCLC: Interim analysis adverse effects[J]. Journal of Clinical Oncology, 2020, 38(15_suppl):9035.
[4] Lemmon C, Videtic G, Murthy SC, et al. A phase I safety and feasibility study of neoadjuvant chemoradiation plus pembrolizumab followed by consolidation pembrolizumab in resectable stage IIIA non-small cell lung cancer[J]. Journal of Clinical Oncology, 2020, 38(15_suppl):9009.
[5] Alex, Herskovic, Elizabeth, et al. Role of postoperative radiotherapy in pathologic stage IIIA (N2) non-small cell lung cancer in a prospective nationwide oncology outcomes database[J]. Journal of Thoracic Oncology, 2017, 12:302.
[6] LePe C. An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Primary end-point analysis of Lung ART. 2020 ESMO Abstract LBA3_PR.
[7] Gray JE, Villegas A, Daniel D, et al. Three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC-update from PACIFIC[J]. J Thorac Oncol, 2020,15(2):288.
[8] Faivre-Finn C. Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC-an update from the PACIFIC trial[J]. J Thorac Oncol, 2020,16(5):860.
[9] Durm GA, Jabbour SK, Althouse SK, et al. A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier cancer research network LUN 14-179[J]. Cancer, 2020,126(19):4353.
[10] Melissa Y. Consolidation nivolumab/ipilimumab versus nivolumab following concurrent chemotherapy in patients with unresectable stage III NSCLC: A planned interim safety analysis from the BTCRC LUN 16-081 trial. 2020 ASCO Abstract 9010.
[11] Jabbour SK, Lee KH, Frost N, et al. Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and radiotherapy as first-line therapy for unresectable, locally advanced stage III NSCLC: KEYNOTE-799[J]. Journal of Clinical Oncology, 2020, 38(15_suppl):9008.
[12] Helen JR. AFT-16: Phase II trial of atezolizumab before and after definitive chemotherapy (CRT) for unresectable stage III non-small cell lung cancer (NSCLC). 2020 ASCO Abstract 9045.
[13] Bi N, Wang L, Xu K, et al. Real-world treatment patterns and clinical outcomes in EGFR-mutant unresectable locally advanced NSCLC (LA-NSCLC): A retrospective multicenter study of 367 patients[J]. Journal of Clinical Oncology, 2020, 38(15_suppl):9047.
[14] Xing L, Wu G, Wang L,et al. Erlotinib versus etoposide/cisplatin with radiation therapy in unresectable stage III epidermal growth factor receptor mutation-positive non-small cell lung cancer: A multicenter, randomized, open-label, phase 2 trial[J]. Int J Radiat Oncol Biol Phys,2020,19:S0360-3016(20)34548-X.
[15] Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): A randomised, two-by-two factorial phase 3 study[J]. Lancet Oncol, 2015,16(2):187.
[16] Bradley JD, Hu C, Komaki RR, et al. Long-term results of NRG oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer[J]. J Clin Oncol, 2020,38(7):706.
[17] Yuan S, Yu Q, Wang S, et al. Individual adaptive radiotherapy versus standard radiotherapy with chemotherapy for patients with locally advanced non-small cell lung cancer: A multicenter randomized phase III clinical trail CRTOG 1601[J]. International Journal of Radiation Oncology*Biology*Physics, 2020,108(3):S105.
[18] Theelen WSME, Peulen HMU, Lalezari F, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial[J]. JAMA Oncol, 2019,5(9):1276.
[19] Theelen WSME, Chen D, Verma V, et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials[J]. Lancet Respir Med, 2020,20:S2213-2600(20)30391-X.
[20] Chmura SJ, Bestvina CM, Karrison TG, et al. Safety and efficacy of a randomized phase I trial to evaluate concurrent or sequential Ipilimumab, Nivolumab, and Stereotactic body radiotherapy in patients with stage IV non-small cell lung cancer (COSINR Study)[J]. International Journal of Radiation Oncology Biology Physics, 2020,108( 3): S72.
[21] Wang X, Bai YF, Zeng M. First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFR ilogometastatic ono-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS)(NCT02893332)[J]. Oncology*Biology*Physics,2020,108(3 Supplement):e81.
[22] Peters S, Pujol J, Dafni U, et al. Consolidation ipilimumab and nivolumab vs observation in limited stage SCLC after chemo-radiotherapy: Results from the ETOP/IFCT 4-12 STIMULI trial[J]. Annals of Oncology,2020,31(4 Supplement): S1211.
[23] Gronberg BH, Killingberg KT, Fltten Y, et al. Randomized phase II trial comparing the efficacy of standard-dose with high-dose twice-daily thoracic radiotherapy (TRT) in limited disease small-cell lung cancer (LD SCLC)[J]. Journal of Clinical Oncology, 2020, 38(15_suppl):9007.
[24] Ii C, Movsas B, Gore EM, et al. A phase 1b/2a study evaluating the pharmacokinetic, safety, and efficacy of nanogenistein in combination with chemoradiotherapy for non-small cell lung cancer[J].International Journal of Radiation Oncology*Biology*Physics,2020,108(3):S103.
[25] Tsakiridis T, Pond G, Wright J, et al. Randomized phase II trial of metformin in combination with chemoradiotherapy (CRT) in locally advanced non-small cell lung cancer (LA-NSCLC); the OCOG-ALMERA trial (NCT02115464)[J]. International Journal of Radiation Oncology Biology Physics, 2020, 108(3):S104.